TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Patrick Gaynes
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

Pasithea Therapeutics reported positive pharmacokinetic data for its PAS-004 tablet in a Phase 1/1b trial for neurofibromatosis type 1 (NF1) patients, demonstrating linear dose-proportionality and improved tablet formulation characteristics.

Insights
KTTA   positive

Reported favorable pharmacokinetic data showing linear dose response, improved tablet formulation, and potential for lower dosing with consistent exposure